Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 299

Results For "treatment"

4031 News Found

A 10-year commission with dedicated mission is required to tackle the upsurge of diabetes in India: says Expert
Healthcare | September 01, 2022

A 10-year commission with dedicated mission is required to tackle the upsurge of diabetes in India: says Expert

India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved


Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian
Clinical Trials | September 01, 2022

Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke


Hydration of proteins could act as a potential marker for an early detection of neuro-degenerative diseases
News | September 01, 2022

Hydration of proteins could act as a potential marker for an early detection of neuro-degenerative diseases

This dense phase often resembles liquid droplets exhibiting higher protein density and weaker molecular motion than the surrounding medium.


Hikma launches seasonal allergic rhinitis nasal spray RYALTRIS in the US
News | August 31, 2022

Hikma launches seasonal allergic rhinitis nasal spray RYALTRIS in the US

This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US


Zydus announces Phase IV DREAM-CKD trial of Desidustat in patients with CDK induced anemia
Clinical Trials | August 31, 2022

Zydus announces Phase IV DREAM-CKD trial of Desidustat in patients with CDK induced anemia

The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.


Merck to present new data of oncology portfolio at ESMO 2022
Clinical Trials | August 30, 2022

Merck to present new data of oncology portfolio at ESMO 2022

Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)


Philips spotlights integrated, data-driven cardiology solutions at ESC 2022
Digitisation | August 28, 2022

Philips spotlights integrated, data-driven cardiology solutions at ESC 2022

Philips AI-powered interventional and diagnostic smart systems enhances diagnostic confidence, drive greater efficiency, and improve patient outcomes


Pristyn Care witnesses industry highest adoption of EMR
Healthcare | August 26, 2022

Pristyn Care witnesses industry highest adoption of EMR

99% of Pristyn Doctors are using EMR facility on its doctor app


Lupin to acquire brands Ondero and Ondero - Met from Boehringer Ingelheim
News | August 25, 2022

Lupin to acquire brands Ondero and Ondero - Met from Boehringer Ingelheim

The cash consideration for the above acquisition will be Euro 26 million.